Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer

Ida Aronchik, Sumit Kar, Yongxian Zhuang, Ethan Ahler, Lick Pui Lai, Vidya Seshadri, Yu Chi Yang, Ashenafi Bulle, Marie Menard, Biswadeep Nayak, Mark P. Labrecque, Julien Dilly, Eejung Kim, Lingyan Jiang, Jason Yano, Urszula N. Wasko, Ciara Helland, Sean Bredeson, Brett Garrick, Yevgeniy Gindin, Brad Sickler, Xing Wei, Kyle Seamon, Jingjing Jiang, Kian-Huat Lim, Matthew Holderfield, Elsa Quintana, Aparna Hegde, Zeena Salman, Alexander Starodub, Alexander Spira, Wungki Park, David S. Hong, Minal Barve, Meredith Pelster, David Sommerhalder, Salman R. Punekar, Ignacio Garrido-Laguna, Brian M. Wolpin, Anirban Maitra, W. Clay Gustafson, Steve Kelsey, Jacqueline A. M. Smith, Kevin K. Lin, Andrew J. Aguirre, Mallika Singh

Open source

DOI: 10.1038/s41591-026-04537-w
Published: 2026-08
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04537-w,
  title = {Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer},
  author = {Ida Aronchik and Sumit Kar and Yongxian Zhuang and Ethan Ahler and Lick Pui Lai and Vidya Seshadri and Yu Chi Yang and Ashenafi Bulle and Marie Menard and Biswadeep Nayak and Mark P. Labrecque and Julien Dilly and Eejung Kim and Lingyan Jiang and Jason Yano and Urszula N. Wasko and Ciara Helland and Sean Bredeson and Brett Garrick and Yevgeniy Gindin and Brad Sickler and Xing Wei and Kyle Seamon and Jingjing Jiang and Kian-Huat Lim and Matthew Holderfield and Elsa Quintana and Aparna Hegde and Zeena Salman and Alexander Starodub and Alexander Spira and Wungki Park and David S. Hong and Minal Barve and Meredith Pelster and David Sommerhalder and Salman R. Punekar and Ignacio Garrido-Laguna and Brian M. Wolpin and Anirban Maitra and W. Clay Gustafson and Steve Kelsey and Jacqueline A. M. Smith and Kevin K. Lin and Andrew J. Aguirre and Mallika Singh},
  year = {2026},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-026-04537-w},
  url = {https://doi.org/10.1038/s41591-026-04537-w}
}

RIS

TY  - JOUR
TI  - Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer
AU  - Ida Aronchik
AU  - Sumit Kar
AU  - Yongxian Zhuang
AU  - Ethan Ahler
AU  - Lick Pui Lai
AU  - Vidya Seshadri
AU  - Yu Chi Yang
AU  - Ashenafi Bulle
AU  - Marie Menard
AU  - Biswadeep Nayak
AU  - Mark P. Labrecque
AU  - Julien Dilly
AU  - Eejung Kim
AU  - Lingyan Jiang
AU  - Jason Yano
AU  - Urszula N. Wasko
AU  - Ciara Helland
AU  - Sean Bredeson
AU  - Brett Garrick
AU  - Yevgeniy Gindin
AU  - Brad Sickler
AU  - Xing Wei
AU  - Kyle Seamon
AU  - Jingjing Jiang
AU  - Kian-Huat Lim
AU  - Matthew Holderfield
AU  - Elsa Quintana
AU  - Aparna Hegde
AU  - Zeena Salman
AU  - Alexander Starodub
AU  - Alexander Spira
AU  - Wungki Park
AU  - David S. Hong
AU  - Minal Barve
AU  - Meredith Pelster
AU  - David Sommerhalder
AU  - Salman R. Punekar
AU  - Ignacio Garrido-Laguna
AU  - Brian M. Wolpin
AU  - Anirban Maitra
AU  - W. Clay Gustafson
AU  - Steve Kelsey
AU  - Jacqueline A. M. Smith
AU  - Kevin K. Lin
AU  - Andrew J. Aguirre
AU  - Mallika Singh
PY  - 2026
JO  - Nature Medicine
DO  - 10.1038/s41591-026-04537-w
UR  - https://doi.org/10.1038/s41591-026-04537-w
ER  -

APA

Aronchik, I., Kar, S., Zhuang, Y., Ahler, E., Lai, L. P., Seshadri, V., Yang, Y. C., Bulle, A., Menard, M., Nayak, B., Labrecque, M. P., Dilly, J., Kim, E., Jiang, L., Yano, J., Wasko, U. N., Helland, C., Bredeson, S., Garrick, B., Gindin, Y., Sickler, B., Wei, X., Seamon, K., Jiang, J., Lim, K., Holderfield, M., Quintana, E., Hegde, A., Salman, Z., Starodub, A., Spira, A., Park, W., Hong, D. S., Barve, M., Pelster, M., Sommerhalder, D., Punekar, S. R., Garrido-Laguna, I., Wolpin, B. M., Maitra, A., Gustafson, W. C., Kelsey, S., Smith, J. A. M., Lin, K. K., Aguirre, A. J., & Singh, M. (2026). Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Nature Medicine. https://doi.org/10.1038/s41591-026-04537-w

Source records

crossref · retrieved 2026-09-25T18:32:55.803Z